Becton Dickinson and (BDX) Given Media Impact Score of 0.21
Headlines about Becton Dickinson and (NYSE:BDX) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Becton Dickinson and earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.3828257033917 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- ETFs with exposure to Becton, Dickinson & Co. : December 18, 2017 (finance.yahoo.com)
- BRIEF-Becton Dickinson And Co Says CEO Vincent Forlenza’s FY 2017 Total Compensation Was $13.1 Mln (reuters.com)
- BRIEF-Becton Dickinson And Co Says CEO Vincent Forlenza’s FY 2017 Total Compensation Was $13.1 Mln (BDX) (markets.businessinsider.com)
- The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB (finance.yahoo.com)
- Becton, Dickinson and (BDX) Price Target Increased to $235.00 by Analysts at Argus (americanbankingnews.com)
Several analysts have recently weighed in on the stock. Argus lifted their target price on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Morgan Stanley lifted their target price on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $230.00 target price (up previously from $210.00) on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Tuesday, October 31st. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $218.36.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter last year, the business earned $2.12 earnings per share. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. research analysts forecast that Becton Dickinson and will post 10.63 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.75 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is 64.52%.
WARNING: “Becton Dickinson and (BDX) Given Media Impact Score of 0.21” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/becton-dickinson-and-bdx-given-media-impact-score-of-0-21/1773291.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.